Cybrexa Therapeutics

Behind every scientific and clinical breakthrough is a team of experts driven by a shared mission to improve patient outcomes and save lives. Cybrexa’s leadership brings deep experience in oncology drug development, clinical trials, and company growth. Together, we are developing the next generation of cancer therapeutics that specifically target tumors and their underlying biology — advancing the future of cancer treatment. Learn more about our bold mission and meet our team: https://bit.ly/4hbRVUm

By focusing on the universal characteristics of tumor biology, Cybrexa's alphalex™- enabled peptide-drug conjugates (PDCs) bypass limitations faced by traditional cancer therapies. Our targeted intracellular delivery of anti-cancer agents and antigen-agnostic approach mean more patients may potentially benefit from our treatments. Learn more about our approach here: https://bit.ly/3CobYzO

Cybrexa Therapeutics presented new preclinical data at #ESMOTAT25, demonstrating the potential of our alphalex™ peptide-drug conjugates to achieve tumor-selective delivery of microtubule inhibitors while sparing healthy cells. Findings showed robust efficacy across multiple tumor models, both as monotherapy and in combination with standard treatments, potentially positioning alphalex PDCs in patients whose solid tumors have progressed following TOP1-based antibody-drug conjugates. Read the full results here: https://bit.ly/3FgoSkf

Cybrexa Therapeutics will present new preclinical findings at #ESMOTAT25, highlighting the potential of our alphalex™ peptide-drug conjugates to achieve tumor-selective delivery while minimizing off-target effects. Poster Presentation: March 3, 2025 Time: 5:15 - 6:15 PM CET Presenter: Vishwas Paralkar, Ph.D. We look forward to sharing insights into how this platform could help address key challenges in oncology. More details here: https://bit.ly/41uXCHv

Our lead clinical-stage program, CBX-12, which utilizes our proprietary alphalex™ platform, showed compelling safety and efficacy across six different tumor types in a robust Phase 1 trial. With activity confirmed, even in heavily pretreated patients with cancer, we are confidently advancing CBX-12 into Phase 2 trials. Learn more about Cybrexa’s peptide-drug conjugates and clinical progress: https://bit.ly/4ggu58J

Cybrexa’s alphalex™ platform leverages a tumor-targeting peptide discovered at Yale, which activates in the acidic microenvironment found in all solid tumors. This unique approach allows us to target cancer cells broadly — regardless of antigen expression — potentially unlocking possibilities where other therapies fall short. Explore our science: https://bit.ly/3CobYzO

We announced today that the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted therapies. CBX-12 is a first-in-class peptide-drug conjugate (PDC) that uses our proprietary alphalex™ technology to enhance the delivery of exatecan, a potent, established TOP1 inhibitor, directly to tumor cells while limiting off-target effects. Learn more at https://bit.ly/4dJDq7S. #biotechnology #oncology #innovation #clinicaltrials

Today, we announced the final results of our Phase 1 study of CBX-12 in patients with advanced or metastatic solid tumors, which were presented at ESMO - European Society for Medical Oncology. The data demonstrate the broad activity of CBX-12 across six tumor types, with a strong response rate in TOP1-naive patients with ovarian and breast cancer, in addition to a favorable safety profile.    Based on this positive data, we have initiated a Phase 2 study of CBX-12 in platinum-resistant ovarian cancer. Read more about CBX-12’s potential for precision targeting and full results: https://bit.ly/3XqMkku   #ESMO24 #Oncology #ClinicalTrials

We look forward to presenting full results from our Phase 1 study of peptide drug conjugate CBX-12 in advanced solid tumors at ESMO - European Society for Medical Oncology. As an antigen-independent therapy, CBX-12 may have broad utility in patients who are not eligible for antigen-targeted therapies. Join us at 12pm CET on Saturday, Sept 14, to learn more: https://bit.ly/3AY8P8K #oncology #ESMO24

#Cybrexa is leading the way in developing revolutionary therapies that target tumors while sparing healthy tissue. Our innovative alphalex™ platform provides a new way to deliver drugs directly into cancer cells without depending on surface antigens. This cutting-edge approach has the potential to improve current #cancertherapeutics. We are dedicated to developing innovative solutions for patients fighting cancer. Stay tuned for some exciting clinical updates. Learn more about our advanced research and technology: http://bit.ly/3yCiugx. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #WeAreCybrexa